At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- BHV-1400 (drug)
- How long the study runs
- Study runs about 24 months (dates as stated)
- About the drug or intervention
- BHV-1400 — drug: BHV-1400 is delivered subcutaneously (SC)
- Patient visit burden
- Not specified by the sponsor
In plain English
This study is looking at a treatment called BHV-1400 for people with IgA nephropathy, a kidney condition. IgA nephropathy happens when a part of the body's defence system builds up in the kidneys and causes damage. The study is run by Biohaven Therapeutics Ltd.
Who can take part
- IgA nephropathy that has been confirmed by a kidney biopsy (a small sample of kidney tissue taken and checked).
Who may not be able to
- IgA nephropathy caused by another condition (known as secondary IgA nephropathy).
- Long-term kidney problems from any cause other than IgA nephropathy.
What taking part involves
- • Not stated — ask the trial team.
Time commitment: Not stated — ask the trial team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years to 65 Years
- Who
- All
- Number of participants
- 20
- Started
- 2025-07-30
- Last checked
- 2026-06
Plain English Summary
What is this study?
- • Testing a new treatment for iga nephropathy
- • Phase1 - 20 participants
- • The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN)
Who can take part?
- • Ages 18 Years to 65 Years
- • Diagnosed with iga nephropathy
Where?
- • Leicester - Site-007
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 65 Years
- Who can join: All genders
Treatment history
Treatments you must have had:
- ✓ biopsy-confirmed IgA Nephropathy
What the study is looking for
- ✓1\. Participants must have biopsy-confirmed IgA Nephropathy
Who cannot take part
- ✗Any secondary IgAN
- ✗Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
See the full criteria
Where Is This Study? (1 UK site)
Site-007
Leicester LE5 4PW, United Kingdom
How to Get in Touch
Chief Medical Officer
Sponsor contactCONTACT